Kodu・Aktsiate loetelu・Kymera Therapeutics Inc

Kymera Therapeutics Inc

Suletud

SektorTervishoid

110.45 0.38

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

108.05

Max

111.61

Põhinäitajad
By Trading Economics
Sissetulek	18M -69M
Müük	32M 34M
Aktsiakasum	-0.71
Kasumimarginaal	-201.467
Töötajad	253
EBITDA	18M -67M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+17.84% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	10. aug 2026

Turustatistika
By TradingEconomics
Turukapital	2.1B 9.1B
Eelmine avamishind	110.07
Eelmine sulgemishind	110.45

Uudiste sentiment

By Acuity

50%

163 / 340 Pingereas Healthcare

Kymera Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. juuli 2026, 18:46 UTC

Kymera Therapeutics Inc. shares are roughly flat as trading fluctuates within a narrow range, reflecting routine activity without specific news.

21. juuli 2026, 19:16 UTC

Kymera Therapeutics Inc is trading higher, supported by broader market strength and optimism in AI stocks, despite a pullback earlier in the session.

20. juuli 2026, 22:16 UTC

Kymera Therapeutics Inc shares are lower in after-market hours. Broader market sentiment is influenced by rising Treasury yields amid interest rate and geopolitical concerns.

Võrdlus sarnastega

Hinnamuutus

Kymera Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

17.84% tõus

12 kuu keskmine prognoos

Keskmine 130.07 USD 17.84%

Kõrge 155 USD

Madal 115 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Kymera Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

16 ratings

Osta

Hoia

Müü

Põhineb 16 analüütiku instrumendi Kymera Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

163 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.